New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma.
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma. Bladder cancer (Amsterdam, Netherlands) Nelson, A. A., Cronk, R. J., Lemke, E. A., Szabo, A., Khaki, A. R., Diamantopoulos, L. N., Grivas, P., Nezami, B. G., MacLennan, G. T., Zhang, T., Hoimes, C. J. 2021; 7 (1): 33-42Abstract
Outcomes of patients with metastatic urothelial carcinoma (mUC) with early bone metastases (eBM) vs no early bone metastases (nBM) have not thoroughly been described in the age of immuno-oncology.To compare survival and other clinical outcomes in patients with eBM and nBM.We used a multi-institutional database of patients with mUC treated with systemic therapy. Demographic, metastatic site, treatment patterns, and clinical outcomes were recorded. Wilcoxon rank-sum, chi-square tests were performed. Survival was estimated by Kaplan-Meier method; multivariable Cox analysis was performed.We identified 270 pts, 67% men, mean age 69±11 years. At metastatic diagnosis, 27% had=1 eBM and were more likely to have de novo vs. recurrent metastases (42% vs 19%, p?
View details for DOI 10.3233/BLC-200377
View details for PubMedID 38993215
View details for PubMedCentralID PMC11181800